Study of Infliximab Therapy for IVIG Treatment-resistant Kawasaki Disease.

Study of Infliximab Therapy for IVIG Treatment-resistant Kawasaki Disease. - KAWASAKIINF01

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1091220086

Enrollment

Registered

2012-04-24

Start date

2012-03-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kawasaki Disease

Interventions

Intervention type:DRUG Name of intervention:Study of Infliximab Therapy for IVIG Treatment-resistant Kawasaki Disease Dose form / Japanese Medical Device Nomenclature:INJECTION Route of administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients against IVIG Treatment-resistant Kawasaki Disease (less than 37.5 degrees C within a 24-hour period)

Exclusion criteria

Exclusion criteria: Past History of Demyelinating Disease Patients less than 6 months of taking BCG Patients with lung thberculosis

Design outcomes

Primary

Measure	Time frame
Complication of Coronary Artery Aneurysm after Infliximab Injection	—

Secondary

Measure	Time frame
Complication of Coronary Artery Aneurysm after Injection (up to One year after Injection) Pyretolysis (within a 48-hour period after injection) Adverse Event	—

Countries

Japan

Contacts

Public ContactHitoshi Kato

National Center for Child Health and Development

+81-3-3416-0181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026